MarketCap
Facebook
X
Telegram
Adaptimmune Therapeutics plc Cash and Cash Equivalents | ADAP
Annual Cash and Cash Equivalents Adaptimmune Therapeutics plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 91.1 M | 144 M | 110 M | 152 M | 61.5 M | 50.4 M | 68.4 M | 84 M | 159 M | 194 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 194 M | 50.4 M | 111 M |
Quarterly Cash and Cash Equivalents Adaptimmune Therapeutics plc
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26.1 M | 41.1 M | 91.1 M | 117 M | 215 M | 144 M | 144 M | 93.1 M | 80.2 M | 121 M | 108 M | 80.7 M | 99.5 M | 91.3 M | 150 M | 44.6 M | 50.5 M | 32.4 M | 56.9 M | 56.9 M | 56.9 M | 56.9 M | 50.4 M | 50.4 M | 50.4 M | 50.4 M | 68.4 M | 68.4 M | 68.4 M | 68.4 M | 84 M | 84 M | 84 M | 84 M | 159 M | 159 M | 159 M | 164 M | 194 M | 194 M | 194 M | 194 M | 102 M | - | 51.2 M | - | - | - | - | - | - | - | 3.11 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 215 M | 3.11 M | 96.5 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AbbVie
ABBV
|
5.23 B | $ 257.12 | 0.86 % | $ 455 B |  USA |
 |
AbCellera Biologics
ABCL
|
129 M | $ 10.89 | 4.11 % | $ 3.25 B |  Canada |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M |  Israel |
 |
Amryt Pharma plc
AMYT
|
113 M | - | - | $ 621 M |  Britain |
 |
Evelo Biosciences
EVLO
|
47.9 M | - | -14.46 % | $ 27.9 M | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
21.3 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K | USA |
 |
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | USA |
 |
Abeona Therapeutics
ABEO
|
78.4 M | $ 5.42 | 0.18 % | $ 287 M | USA |
 |
iTeos Therapeutics
ITOS
|
142 M | - | - | $ 411 M | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
3.98 M | $ 4.63 | 21.05 % | $ 20 M | Israel |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
248 M | - | -0.23 % | $ 916 M | USA |
 |
BioXcel Therapeutics
BTAI
|
28.4 M | $ 0.07 | 9.81 % | $ 855 K | USA |
 |
Allakos
ALLK
|
17.8 M | - | - | $ 28.6 M | USA |
 |
Cyclerion Therapeutics
CYCN
|
2.82 M | $ 23.52 | 458.67 % | $ 98.9 M | USA |
 |
Lexicon Pharmaceuticals
LXRX
|
34.3 M | $ 2.0 | 0.3 % | $ 726 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
30 M | - | 3.16 % | $ 1.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
43.9 M | - | - | $ 2.17 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
18 M | $ 5.12 | 0.1 % | $ 981 M | Canada |
 |
Ampio Pharmaceuticals
AMPE
|
4.09 M | - | -11.43 % | $ 502 K | USA |
 |
NextCure
NXTC
|
26 M | $ 7.0 | 0.55 % | $ 19.9 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
4.88 M | - | 17.91 % | $ 11.1 M | USA |
 |
Nanobiotix S.A.
NBTX
|
52.8 M | $ 37.01 | 0.27 % | $ 1.77 T |  France |
 |
ACADIA Pharmaceuticals
ACAD
|
178 M | $ 27.83 | 0.32 % | $ 4.69 B | USA |
 |
Axcella Health
AXLA
|
17.1 M | - | -16.42 % | $ 249 M | USA |
 |
SQZ Biotechnologies Company
SQZ
|
63.7 M | - | 57.95 % | $ 12.8 M | USA |
 |
Atreca
BCEL
|
30.8 M | - | -11.76 % | $ 5.79 M | USA |
 |
Berkeley Lights
BLI
|
86.5 M | - | -7.31 % | $ 87 M | USA |
 |
Bellerophon Therapeutics
BLPH
|
6.92 M | - | -74.18 % | $ 955 K | USA |
 |
Achieve Life Sciences
ACHV
|
20.9 M | $ 7.06 | 0.41 % | $ 308 M | USA |
 |
Baudax Bio
BXRX
|
5.26 M | - | 0.59 % | $ 63 K | USA |
 |
Calithera Biosciences
CALA
|
25.5 M | - | -10.95 % | $ 876 K | USA |
 |
CymaBay Therapeutics
CBAY
|
207 M | - | - | $ 3.45 B | USA |
 |
Codiak BioSciences
CDAK
|
76.9 M | - | -55.98 % | $ 2.15 M | USA |
 |
ChemoCentryx
CCXI
|
50 M | - | - | $ 3.74 B | USA |
 |
Avid Bioservices
CDMO
|
38.1 M | - | - | $ 789 M | USA |
 |
AC Immune SA
ACIU
|
26.8 M | $ 2.76 | 2.6 % | $ 278 M |  Schweiz |
|
Cerevel Therapeutics Holdings
CERE
|
416 M | - | - | $ 7.29 B | USA |
 |
Aclaris Therapeutics
ACRS
|
20 M | $ 5.32 | 1.27 % | $ 652 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
6.6 M | - | - | $ 169 M | USA |
 |
Adagene
ADAG
|
74.5 M | $ 3.4 | 2.72 % | $ 201 M |  China |
 |
ADC Therapeutics SA
ADCT
|
261 M | $ 1.07 | 0.45 % | $ 136 M | Schweiz |
 |
Adial Pharmaceuticals
ADIL
|
5.88 M | $ 4.9 | 0.08 % | $ 3.28 M | USA |
 |
ADMA Biologics
ADMA
|
87.6 M | $ 9.23 | 0.16 % | $ 2.2 B | USA |
 |
Adaptive Biotechnologies Corporation
ADPT
|
70.5 M | $ 24.2 | 0.08 % | $ 3.67 B | USA |
 |
Agenus
AGEN
|
3 M | $ 6.94 | 0.73 % | $ 206 M | USA |
 |
Agios Pharmaceuticals
AGIO
|
89.1 M | $ 33.6 | 0.16 % | $ 1.95 B | USA |